⭐AML Hub spotlight: Findings from the cAMeLot-1 trial of bleximenib⭐. @DrEmmaSearle, @TheChristieNHS, shared findings at #ASH24 from the ongoing phase I/II cAMeLot-1 trial of bleximenib in patients with R/R KMT2Ar or NPM1m acute leukemia. #AMLsm #leusm #MedEd.

New data 📝 Updated results from the phase I KOMET-007 trial, presented by Harry Erba at #EHA2025, show robust clinical activity of ziftomenib with intensive induction chemotherapy in ND NPM1m and KMT2Ar AML. Learn more: #AMLsm #leusm #MedNews #MedEd

🚨 News 🚨. @US_FDA has accepted the supplemental new drug application for decitabine + cedazuridine in combination with venetoclax for adults with newly diagnosed AML, with an assigned PDUFA target action date of Feb 25, 2026. Read more: #AMLsm #leusm

🚨Catch up on the latest developments in real-world studies and risk stratification of acute myeloid leukemia from #EHA2025, with social media coverage from the AML Hub. Read more: #AMLsm #leusm #MedNews #MedEd

📝 A new study published in @BMTjournal indicates that common barriers to HSCT in patients with TP53m AML include infection, concurrent other cancer, and relapse within <3 months post-remission. More news: #AMLsm #leusm #MedEd

New publication📝 A retrospective analysis of barriers to HSCT and outcomes post-HSCT in patients with TP53m AML published in @BMTjournal found favorable outcomes post-HSCT regardless of pre-HSCT OR, cCR, or MRD negativity. Learn more: #AMLsm #leusm

🎧 New podcast! . Listen to @CharlieCraddock, Queen Elizabeth Hospital Birmingham, UK, sharing the closing remarks from the @Know_AML HCP–patient webinar, titled ‘Mutation testing in AML: What you need to know’. Listen: Watch:

To conclude the @Know_AML HCP-patient webinar, titled ‘Mutation testing in AML: What you need to know’, the faculty shared their closing remarks and addressed questions from the audience. Watch the full video here: #KnowAML #AMLsm #leusm

Thank you to our funders, who make it possible for us to deliver the AML Hub. • Daiichi Sankyo .• Hippocrate Conference Institute, an association of the Servier Group .• Johnson & Johnson .• Kura Oncology .• Syndax . #leusm

🚨Catch up on the latest developments in HSCT for the treatment of acute myeloid leukemia from #EHA2025, with social media coverage from the AML Hub. Read more: #AMLsm #leusm #MedNews #MedEd

📝 A new study published in @AjHematology by @jayastuMD et al. found that in venetoclax-treated genomic secondary AML, TP53 mutations and adverse cytogenetics were linked to higher mortality. ELN 2024 risk categories added further prognostic value. More news:

New publication 📝 A retrospective analysis published in @AjHematology by @jayastuMD et al. reports similar OS and RFS in clinical secondary AML and genomic secondary AML – both significantly shorter than in de novo AML. Outcomes with venetoclax vary by genomic subtype. Learn

🚨 News 🚨. The supplemental new drug application for revumenib in relapsed/refractory NPM1-mutated AML has been granted priority review by the @US_FDA. Read more: #AMLsm #leusm #MedNews #MedEd

🚨Catch up on the latest developments in novel agents and combinations for the treatment of acute myeloid leukemia from #EHA2025 with social media coverage from the AML Hub. Read more: #AMLsm #leusm #MedNews #MedEd

During the @Know_AML patient and HCP webinar, Gail J. Roboz, @WeillCornell, and Ralph Hills, Connecticut, US, discussed how physicians and patients can communicate more clearly about mutation testing in AML. Watch the full video here: #KnowAML #AMLsm

🚨 News 🚨. @US_FDA has granted priority review to the supplemental new drug application for revumenib in relapsed/refractory NPM1-mutated AML, with an assigned PDUFA target action date of October 25, 2025. Read more: #AMLsm #leusm #MedNews #MedEd

🎧 New podcast! . Listen to Gail J. Roboz, @WeillCornell, and Ralph Hills, Connecticut, US, discussing how physicians and patients can communicate more clearly about mutation testing in AML, during an HCP–patient webinar hosted by @Know_AML. Listen:

During the @Know_AML patient and HCP webinar, Gail J. Roboz, @WeillCornell, @CharlieCraddock, Queen Elizabeth Hospital Birmingham, and Ralph Hills, Know AML Chair, discussed benefits of participating in clinical trials, including improved access to mutation testing methods in

🚨 News 🚨.@EMA_News has granted orphan drug designation to PHI-101, a next-generation AI-designed FLT3 inhibitor, for the treatment of AML. Read more: . #AMLsm #MedEd #MedNews

🚨 News 🚨. @US_FDA has cleared the investigational new drug application for a phase I study of the selective BCL2 inhibitor lonitoclax in combination with azacitidine for the treatment of patients with relapsed/refractory AML. Read more: #AMLsm #leusm

🚨 News 🚨. The CHMP of the @EMA_News has recommended granting conditional marketing authorization to a novel, cryopreserved HSCT product containing dorocubicel and unexpanded CD34- cells, each derived from the same cord blood unit, for the treatment of adults with hematologic